DermaVir Patch

Clinical data indicates that DermaVir Patch may be most effective when administered six times a year during three-hour treatment sessions. Results also suggest that the nanomedicine candidate may benefit currently undertreated HIV-infected individuals, including patients with early stage HIV who have not yet received drugs, as well as later stage, drug-resistant disease.

DermaVir Patch initially demonstrated immunological and antiviral activities in non-human primates with AIDS (Lisziewicz et al AIDS 2005). These studies suggested that a cumulative strengthening of antiviral immune response can be achieved through repeated DermaVir Patch administration without causing significant toxicities or adverse effects.

Recently published clinical data demonstrated that a single administration of the DermaVir Patch induced new HIV-specific T-cell Precursors with High Proliferative Capacity (PHPC) in a dose-dependent manner. An independent study demonstrated that PHPC count inversely correlates with viral load.

Clinical data on the DermaVir Patch appears to confirm and extend pre-clinical results. Results from primates and humans from these studies form the basis for DermaVir Patch's clinical development path.